Healthcare · NIFTY 500
Glenmark Pharmaceuticals Limited
₹2,632.90 -7.10 (-0.27%) Updated 16 Nov, 10:47 pm IST
Today
- Open
- ₹2,643.00
- Prev close
- ₹2,640.00
- Day high
- ₹2,686.30
- Day low
- ₹2,620.00
- Volume
- 3.51 L
- Value traded
- ₹93.16 Cr
- Upper circuit
- ₹2,705.80
- Lower circuit
- ₹2,548.20
- 52W high
- ₹2,714.00
- 52W low
- ₹1,807.00
- 1 month
- +17.31%
- 6 months
- +12.83%
Ratios
Key numbers
Worked out from the latest filings (Consolidated) and today's price. TTM = last four quarters.
Quarterly results
Results for each quarter
Last 12 quarters, consolidated, ₹ crore. Hover a bar to see the number.
Revenue and net profit
Revenue · QoQ (vs last quarter)
Revenue · YoY (vs a year ago)
Net profit · QoQ (vs last quarter)
Net profit · YoY (vs a year ago)
EPS (₹) · YoY (vs a year ago)
| ₹ Cr | Dec 23 | Mar 24 | Jun 24 | Sep 24 | Dec 24 | Mar 25 | Jun 25 | Sep 25 | Dec 25 | Mar 26 | Jun 26 | Sep 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2,507 | 3,063 | 3,244 | 3,434 | 3,388 | 3,256 | 3,264 | 6,047 | 3,901 | 3,771 | 4,018 | 4,157 |
| Other income | 45.4 | 773 | 31.5 | 39.4 | 31.1 | 11.7 | 26.4 | 201 | 44.5 | 189 | 65.8 | 92.8 |
| Total income | 2,552 | 3,836 | 3,276 | 3,473 | 3,419 | 3,268 | 3,291 | 6,247 | 3,945 | 3,960 | 4,084 | 4,250 |
| Raw material | 658 | 754 | 686 | 774 | 746 | 795 | 732 | 723 | 775 | 731 | 601 | 838 |
| Purchases | 413 | 211 | 360 | 443 | 418 | 345 | 581 | 620 | 749 | 446 | 661 | 530 |
| Employee cost | 753 | 701 | 710 | 787 | 788 | 737 | 763 | 1,086 | 841 | 887 | 935 | 1,028 |
| Other expenses | 930 | 862 | 835 | 975 | 915 | 870 | 906 | 1,337 | 894 | 948 | 1,033 | 1,050 |
| Total expenses | 2,997 | 2,859 | 2,813 | 3,001 | 2,962 | 2,887 | 2,872 | 3,895 | 3,227 | 3,199 | 3,441 | 3,628 |
| Operating profit | -285 | 57.6 | 588 | 602 | 600 | 188 | 257 | 974 | 685 | 389 | 805 | 490 |
| OPM % | -11.4% | 1.9% | 18.1% | 17.5% | 17.7% | 5.8% | 7.9% | 16.1% | 17.6% | 10.3% | 20.0% | 11.8% |
| Finance cost | 134 | 149 | 39.6 | 48.5 | 52.3 | 66.7 | 58.2 | 66.5 | 41.4 | 42.6 | 54.0 | 63.8 |
| Depreciation | 147 | 151 | 118 | 120 | 123 | 125 | 130 | 141 | 154 | 148 | 173 | 180 |
| Exceptional items | -76.7 | -447 | — | — | — | -373 | -323 | -1,385 | -184 | -373 | — | -284 |
| Profit before tax | -521 | 531 | 462 | 473 | 456 | 8.0 | 95.6 | 967 | 534 | 388 | 643 | 338 |
| Tax | -71.8 | 1,769 | 122 | 118 | 108 | 3.6 | 48.6 | 357 | 131 | 86.4 | 161 | 74.5 |
| Net profit | -331 | -1,214 | 340 | 354 | 348 | 4.4 | 47.0 | 610 | 403 | 301 | 483 | 264 |
| Profit to shareholders | -351 | -1,218 | — | 0.0 | 0.0 | 4.7 | 46.9 | 610 | 403 | -0.1 | 483 | 0.0 |
| EPS (₹) | -12.45 | -43.18 | 12.06 | 12.55 | 12.33 | 0.16 | 1.66 | 21.62 | 14.28 | 10.68 | 17.11 | 9.34 |
Profit & loss
Results for each year
8 financial years (April to March), consolidated, ₹ crore.
Sales, operating profit and net profit
Revenue · YoY (vs a year ago)
Net profit · YoY (vs a year ago)
| ₹ Cr | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 9,865 | 10,641 | 10,944 | 12,305 | 12,990 | 11,813 | 13,322 | 16,983 |
| Other income | 208 | 160 | 50.2 | 167 | 317 | 840 | 114 | 461 |
| Total expenses | 8,940 | 9,737 | 9,656 | 10,769 | 11,673 | 11,716 | 11,663 | 13,192 |
| Employee cost | 2,056 | 2,255 | 2,344 | 2,447 | 2,781 | 2,868 | 3,022 | 3,578 |
| Operating profit | 1,753 | 1,731 | 2,129 | 2,059 | 1,513 | 294 | 1,979 | 2,306 |
| OPM % | 17.8% | 16.3% | 19.5% | 16.7% | 11.6% | 2.5% | 14.9% | 13.6% |
| Finance cost | 335 | 377 | 353 | 298 | 350 | 516 | 207 | 209 |
| Depreciation | 326 | 417 | 444 | 487 | 611 | 582 | 486 | 573 |
| Profit before tax | 1,301 | 1,096 | 1,382 | 1,441 | 868 | 36.5 | 1,399 | 1,985 |
| Tax | 376 | 320 | 412 | 448 | 491 | 1,867 | 352 | 623 |
| Tax rate % | 28.9% | 29.2% | 29.8% | 31.1% | 56.5% | 5,116.7% | 25.2% | 31.4% |
| Net profit | 925 | 776 | 970 | 994 | 377 | -1,434 | 1,047 | 1,362 |
| Profit to shareholders | 0.0 | 0.0 | 0.0 | 942 | 0.0 | -1,502 | 1,047 | 0.1 |
| Net margin % | 0.0% | 0.0% | 0.0% | 7.7% | 0.0% | -12.7% | 7.9% | 0.0% |
| EPS (₹) | 32.78 | 27.50 | 34.38 | 33.37 | 10.53 | -53.22 | 37.10 | 48.24 |
Balance sheet
Assets and debt
At each year end (and the latest half year), ₹ crore.
Equity, debt and assets
Shareholders' equity · YoY (vs a year ago)
| ₹ Cr | Mar 23 | Mar 24 | Mar 25 | Mar 26 | Sep 26 |
|---|---|---|---|---|---|
| Shareholders' equity | 9,474 | 7,848 | 8,849 | 10,512 | 11,212 |
| Long-term borrowings | 3,852 | 0.0 | 513 | 0.0 | 0.0 |
| Short-term borrowings | 496 | 991 | 1,681 | 0.0 | 867 |
| Total borrowings | 4,348 | 991 | 2,194 | — | 867 |
| Current liabilities | 5,046 | 5,819 | 5,967 | 6,376 | 7,507 |
| Fixed assets (PPE) | 3,904 | 3,118 | 3,319 | 3,890 | 3,307 |
| Inventories | 2,978 | 2,513 | 3,029 | 3,431 | 3,746 |
| Trade receivables | 4,099 | 1,858 | 3,342 | 4,963 | 5,494 |
| Cash & equivalents | 1,443 | 1,658 | 1,676 | 1,175 | 1,290 |
| Current assets | 9,874 | 7,428 | 9,295 | 11,300 | 12,714 |
| Total assets | 19,372 | 14,359 | 16,050 | 19,908 | 21,400 |
| Debt / equity | 0.46 | 0.13 | 0.25 | — | 0.08 |
Cash flow
Cash coming in and going out
For each financial year, ₹ crore. Free cash flow = cash from operations minus spending on fixed assets.
Operating, investing and financing cash
Operations · YoY (vs a year ago)
| ₹ Cr | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Cash from operations | 1,109 | 625 | -265 | -828 | 3,445 |
| Cash from investing | -333 | -528 | 4,369 | 2.1 | -1,283 |
| Cash from financing | -520 | -77.5 | -3,906 | 787 | -2,709 |
| Spent on fixed assets | -790 | -608 | -898 | -750 | -1,358 |
| Free cash flow | 319 | 17.6 | -1,164 | -1,577 | 2,087 |
| Net cash flow | 255 | 19.4 | 198 | -38.5 | -547 |
Shareholding
Who holds the shares
Promoter and public holding at each quarter end, as filed with NSE.
Holding over time
Latest (30 Sep 2026)
- Promoter & group
- 46.65%
- Public (FIIs, mutual funds, retail…)
- 53.35%
- Promoter change, last quarter
- 0.00 pts
Dividends & news
Latest dividends and announcements
Dividends & corporate actions
- Dividend - Rs 2.50 Per Share
- Interim Dividend - Rs 2.50 Per Share
- Dividend - Rs 2.50 Per Share
- Dividend - Rs 2.50 Per Share
- Dividend - Rs 2.50 Per Share
- Annual General Meeting/Dividend - Rs 2.50 Per Share
- Annual General Meeting/Dividend - Rs 2.50 Per Share
- Annual General Meeting/Dividend - Rs 2.50 Per Share
Board meetings
- GLENMARK PHARMACEUTICALS LIMITED has informed the Exchange about Board Meeting to be held on 05-Nov-2026 to inter-alia consider and approve the Unaud…
- the financial results for the period ended September 30, 2026
- GLENMARK PHARMACEUTICALS LIMITED has informed the Exchange about Board Meeting to be held on 31-Jul-2026 to inter-alia consider and approve the Unaud…
- the financial results for the period ended Jun 30, 2026
- the Yearly Audited Financial results of the Company for the period ended March 2026 and Dividend.
Filings with NSE
- Press Release
- Analysts/Institutional Investor Meet/Con. Call Updates
- Analysts/Institutional Investor Meet/Con. Call Updates
- Analysts/Institutional Investor Meet/Con. Call Updates
- Analysts/Institutional Investor Meet/Con. Call Updates
- Analysts/Institutional Investor Meet/Con. Call Updates
- Analysts/Institutional Investor Meet/Con. Call Updates
Latest news
Glenmark Shares Rise 1.4% on US Cancer Drug LaunchHDFC Sky · 16 Nov, 10:15 amGlenmark shares rise after US arm launches cancer therapy drugCNBC TV18 · 16 Nov, 10:07 amGlenmark Shares Rise After Launching Generic Cancer Drug in USEquitypandit · 16 Nov, 11:48 amGlenmark launches authorized generic of Axitinib tablets in the USAscanx.trade · 16 Nov, 8:50 amPharma shares shine: Sai, Gland, Divi's, Laurus, Glenmark surge up to 9%Business Standard · 9 Nov, 12:23 pmMissed Glenmark's Run? Here Is What Holders SawSimply Wall St · 15 Nov, 10:47 pmGLENMARK Outlook for the WeekEquitypandit · 8 Nov, 1:30 pmStock to buy today: Glenmark Pharmaceuticals (₹2,270) – BUYBusinessLine · 7 Jul, 12:30 pmAbout
About Glenmark Pharmaceuticals Limited
Glenmark Pharmaceuticals Limited is an Indian multinational pharmaceutical company based in Mumbai. Founded in 1977 by Gracias Saldanha as a generic drug and active pharmaceutical ingredient manufacturer, it is listed on the Bombay Stock Exchange and the National Stock Exchange of India. We unite scientific excellence, responsible execution and commercial agility to effectively address unmet patient needs of today and proactively anticipate the emerging health needs of tomorrow.The company produces and distributes medicines in more than 80 countries, with operations concentrated in India, North America, Europe, and emerging markets. As of March 2026, it employed approximately 17,000 people. Its name derives from Saldanha's sons, Glenn and Mark.
From Wikipedia (CC BY-SA 4.0).
BRANDS
Company details
- Company name
- Glenmark Pharmaceuticals Limited
- NSE symbol
- GLENMARK
- BSE scrip code
- 532296
- ISIN
- INE935A01035
- Listed on
- NSE, BSE
- Series
- EQ (normal equity)
- Listed on NSE since
- 7 Feb 2000
- Face value
- ₹1 per share
- Market lot
- 1 share
- Shares issued
- 28.22 crore
- Index
- NIFTY 500
- Sector (NSE)
- Healthcare
- Industry
- Pharmaceuticals: Major
- Managing director / CEO
- Glenn Saldanha
- Chair
- Glenn Saldanha
- Headquarters
- Mumbai
- Registered address
- Glenmark House, B. D. Sawant Marg, Chakala, Off Western Express Highway, Andheri (E), Mumbai - 400 099, Maharashtra, India
- Founded
- 1977
- Employees
- 17,782
- Financial year
- April to March
- Results basis
- Consolidated
- Website
- glenmarkpharma.com
Peers
Other Healthcare stocks
-
LAURUSLABSLaurus Labs ₹2,220.00 -8.42%
-
DIVISLABDivi's Laboratories ₹11,080.00 -3.16%
-
MAXHEALTHMax Healthcare Institute ₹1,009.90 +6.63%
-
APOLLOHOSPApollo Hospitals Enterprise ₹8,771.00 +2.87%
-
NATCOPHARMNATCO Pharma ₹828.65 +2.25%
-
AUROPHARMAAurobindo Pharma ₹1,794.00 -1.60%
-
PPLPHARMAPiramal Pharma ₹244.93 +0.16%
-
FORTISFortis Healthcare ₹803.20 +5.13%
Prices from NSE via Upstox. Financials from the company's results filed with NSE (XBRL); ratios are our own working. Profile from global-stock-logos (MIT). For information only, not a recommendation to buy or sell.